Jade Biosciences (JBIO) Free Cash Flow (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Free Cash Flow data on file, last reported at -$24.1 million in Q1 2026.

• Quarterly Free Cash Flow fell 28.9% year-over-year to -$24.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$100.1 million (down 110.59% YoY) and the FY2025 annual result came in at -$94.7 million, down 34.13% from the prior year.
• Free Cash Flow grew to -$24.1 million in Q1 2026, from -$33.5 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $2.5 million in Q2 2024 to a low of -$33.5 million in Q4 2025.
• A 5-year average of -$15.8 million and a median of -$15.6 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2024 — Free Cash Flow surged 116.77% — and 2025, when it tumbled 902.67%.
• Tracing JBIO's Free Cash Flow over 5 years: stood at -$16.5 million in 2022, then increased by 10.36% to -$14.8 million in 2023, then slumped by 53.99% to -$22.8 million in 2024, then plunged by 46.69% to -$33.5 million in 2025, then gained by 28.07% to -$24.1 million in 2026.
• The last three Free Cash Flow figures came in at -$24.1 million (Q1 2026), -$33.5 million (Q4 2025), and -$22.4 million (Q3 2025), per Business Quant data.